Abstract:Esophageal cancer is a highly malignant disease with poor prognosis. Despite recent advances in the study of esophageal cancer, there has been only limited improvement in the treatment and prognosis. N6-methyladenosine (m6A), a type of RNA modification, has been extensively investigated and is involved in many biological behaviors, including tumorigenesis and progression. Thus, more research on m6A modification may increase our understanding of esophageal cancer pathogenesis and provide potential targets. In our study, we integrated the public data of esophageal cancer from The Cancer Genome Atlas (TCGA) and Gene-Expression Omnibus (GEO) databases. Unsupervised clustering analysis was used to classify patients into different groups. Gene set variation analysis (GSVA) was performed in a nonparametric and unsupervised mode. We evaluated immune cell infiltration by single sample gene set enrichment analysis (ssGSEA). Differentially expressed genes (DEGs) among m6A clusters were identified using Empirical Bayesian approach. Both multivariate and univariate Cox regression models were used for prognostic analysis. We provided an overview of gene variation and expression of 23 m6A regulators in esophageal cancer, as well as their effects on survival. Based on the overall expression level of m6A regulators, patients were classified into three m6A clusters (A-C) with different immune cell infiltration abundance, gene expression signatures and prognosis. Among m6A clusters, we identified 206 DEGs, according to which patients were classified into 4 gene clusters (A-D). Quantitative m6A score was calculated for each patient based on those DEGs with significant impact on survival. The infiltration of all types of immune cells except type 2 T helper (Th2) cells were negatively correlated with m6A score. M6Acluster C exhibited the lowest m6A score, the most abundant immune cell infiltration, and the worst prognosis, suggesting an immune excluded phenotype. Consistently, gene cluster D with the lowest m6A score showed the worst prognosis. In short, patients with esophageal cancer showed different m6A modification patterns. Quantitative scoring indicated that patients with the lowest m6A score exhibited the most abundant immune cell infiltration and the poorest prognosis. This m6A scoring system is promising to assess m6A modification pattern, characterize immune infiltration and guide personalized treatment and prognostic prediction.

The Implications of N6-methyladenosine (m6a) Modification in Esophageal Carcinoma

Interaction Between N6-methyladenosine Modification and the Tumor Microenvironment in Colorectal Cancer

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Recent advances of m6A methylation modification in esophageal squamous cell carcinoma

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

N<SUP>6</SUP>-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

The Role of m<SUP>6</SUP>A Modification and m<SUP>6</SUP>A Regulators in Esophageal Cancer

The momentous role of N6-methyladenosine in lung cancer

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

Roles and Implications of Mrna N6 -Methyladenosine in Cancer.

Roles and implications of mRNA N 6 ‐methyladenosine in cancer

Functions of N6-methyladenosine and Its Role in Cancer

Link Between M6a Modification and Cancers

m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer

RNA M6a Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers

Comprehensive analysis of m6A RNA methylation regulators in esophageal carcinoma

The Crucial Roles of N6-methyladenosine (m6a) Modification in the Carcinogenesis and Progression of Colorectal Cancer

m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer

N6-methyladenosine (m6a) RNA Modification in Tumor Immunity

N6-methyladenosine Modification of Noncoding RNAs: Mechanisms and Clinical Applications in Cancer